Diastolic heart failure: The forgotten manifestation of hypertensive heart disease Rigobert Lapu-BulaElizabeth Ofili OriginalPaper Pages: 164 - 170
Vascular abnormalities in hypertension: Cause, effect, or therapeutic target? Gary E. McVeighRick PlumbSinead Hughes OriginalPaper Pages: 171 - 176
Is proteinuria a plausible target of therapy? Dave C. Y. ChuaGeorge L. Bakris OriginalPaper Pages: 177 - 181
Is the angiotensin ii type 2 receptor cerebroprotective? Albert FournierJean Michel AchardFranz Messerli OriginalPaper Pages: 182 - 189
Pulse pressure, heart rate, and drug treatment of hypertension Michel E. Safar OriginalPaper Pages: 190 - 194
Aldosterone and aldosterone antagonism in systemic hypertension William H. FrishmanCharles T. Stier Jr OriginalPaper Pages: 195 - 200
Prevention of dementia and cerebroprotection with antihypertensive drugs Olivier HanonMarie Laure SeuxFrançoise Forette OriginalPaper Pages: 201 - 207
Clinical trials report Kathleen H. BerecekAmal FaragSamy I. McFarlane BriefCommunication Pages: 211 - 214
Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management Fadi El-AtatSamy I. McFarlaneJames R. Sowers OriginalPaper Pages: 215 - 223
Adrenocortical hypertension Angelo CapricchioneNathaniel WinerJames R. Sowers OriginalPaper Pages: 224 - 229
Obesity-related hypertension: Is there a role for selective leptin resistance? Marcelo L. G. CorreiaWilliam G. Haynes OriginalPaper Pages: 230 - 235
Leptin, sympathetic nervous system, and baroreflex function Guido Grassi OriginalPaper Pages: 236 - 240
The global epidemic of obesity: Are we becoming more sympathetic? Kevin P. Davy OriginalPaper Pages: 241 - 246